Evaluation of Cutaneous Acceptability and Perceived Effectiveness of a Nasal Spray (Health Care Products)
Primary Purpose
Acceptance, Social, Sensitivity, Contact
Status
Completed
Phase
Not Applicable
Locations
Brazil
Study Type
Interventional
Intervention
Hyaluronic Nasal Spray
Sponsored by
About this trial
This is an interventional other trial for Acceptance, Social
Eligibility Criteria
Inclusion Criteria:
- Phototype (Fitzpatrick): I to VI.
- User of the same product category.
- Have intact skin in the study region.
- Agree to adhere to the study procedures and requirements: study time, returns (after 28 days) to the laboratory to perform the study procedures, home use of the investigational product, filling in the use diary, not changing facial cosmetic habits during the period of study.
- Agree not to perform facial aesthetic dermatological treatments until the end of the study (28 days), such as: peelings, laser, fillers, use of any facial cosmetics.
- Agree to adhere to the requirements of the study in the fight against the COVID-19 pandemic, through preventive measures: use a mask according to WHO guidelines; use the mask while traveling to the research center and during the study procedures; maintain social distancing; wash hands frequently with soap and/or alcohol gel and go to the research center only at scheduled times to avoid agglomerations.
- Signing of the Free and Informed Consent Term (FICT).
Exclusion Criteria:
- Pregnant or lactating women.
- Skin tags in the experimental area that interfere in the assessment of possible skin reactions (pigmentation disorders, vascular malformations, scars, increased hairiness, large amounts of freckles and warts, sunburn).
- Presence of active dermatoses or skin lesions (local and/or disseminated) in the study region.
- Carriers of corneal ulcerations, keratoconus, blepharitis, meibomitis, pterygium, chemosis, hyperemia or other active eye diseases of moderate or severe intensity.
- History of ineffectiveness, allergic reactions, irritation or intense discomfort sensation to topical products: cosmetics or medicines.
- Expected vaccination during the study or up to 3 weeks before the study;
- History of pathologies aggravated or triggered by ultraviolet radiation.
- Use of non-steroidal anti-inflammatory drugs, corticosteroids, antihistamines, photosensitizers or immunosuppressants up to 2 weeks before the study.
- Facial aesthetic or dermatological treatment up to 4 weeks before the study.
- Hormonal treatments not stable in the last 3 months.
- Hyperpigmentation associated with the use of drugs such as tetracycline, phenothiazides, or amiodarone.
- Hyperpigmentation associated with photosensitivity.
- Actinic lichen planus;
- People directly involved in carrying out this study and their families.
- Be participating in another study.
- History of non-adherence or unwillingness to adhere to the study protocol.
- Intense sun exposure or tanning session up to 15 days before the initial assessment;
- Any condition not mentioned above that, in the opinion of the investigator, could compromise the evaluation of the study.
Sites / Locations
- Kosmoscience Ciência e Tecnologia Cosmética Ltda
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Experimental
Arm Description
Outcomes
Primary Outcome Measures
Erythema degree or absence
Erythema evaluation according to International Contact Dermatitis Research Group
Secondary Outcome Measures
Full Information
NCT ID
NCT05508230
First Posted
August 18, 2022
Last Updated
July 20, 2023
Sponsor
Herbarium Laboratorio Botanico Ltda
1. Study Identification
Unique Protocol Identification Number
NCT05508230
Brief Title
Evaluation of Cutaneous Acceptability and Perceived Effectiveness of a Nasal Spray (Health Care Products)
Official Title
Clinical Study to Evaluate the Safety of the Investigational Product NASAL SPRAY Through of Assessments of Cutaneous Acceptability and Perceived Efficacy Under Normal Conditions of Use
Study Type
Interventional
2. Study Status
Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
May 15, 2023 (Actual)
Primary Completion Date
June 12, 2023 (Actual)
Study Completion Date
June 12, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Herbarium Laboratorio Botanico Ltda
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a clinical study for health care product safety assessment. The research is going to conducted with 45 subjects, aged 18 to 70 years, women users of the product category, regardless of color/race, ethnicity, sexual orientation, classes and social groups and who must present all the other characteristics of the inclusion criteria and no exclusion characteristics. The product is applied under real conditions of use, in a panel of survey participants corresponding to the target consumers. Medical evaluation will be available throughout the study to assess possible adverse events. The main of the study is to observe the effects of the application of the product on the skin and prove the absence of irritability and/or allergy and perceived acceptability.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acceptance, Social, Sensitivity, Contact
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
45 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Experimental
Arm Type
Experimental
Intervention Type
Other
Intervention Name(s)
Hyaluronic Nasal Spray
Intervention Description
Health care product - nasal application
Primary Outcome Measure Information:
Title
Erythema degree or absence
Description
Erythema evaluation according to International Contact Dermatitis Research Group
Time Frame
28 days
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Phototype (Fitzpatrick): I to VI.
User of the same product category.
Have intact skin in the study region.
Agree to adhere to the study procedures and requirements: study time, returns (after 28 days) to the laboratory to perform the study procedures, home use of the investigational product, filling in the use diary, not changing facial cosmetic habits during the period of study.
Agree not to perform facial aesthetic dermatological treatments until the end of the study (28 days), such as: peelings, laser, fillers, use of any facial cosmetics.
Agree to adhere to the requirements of the study in the fight against the COVID-19 pandemic, through preventive measures: use a mask according to WHO guidelines; use the mask while traveling to the research center and during the study procedures; maintain social distancing; wash hands frequently with soap and/or alcohol gel and go to the research center only at scheduled times to avoid agglomerations.
Signing of the Free and Informed Consent Term (FICT).
Exclusion Criteria:
Pregnant or lactating women.
Skin tags in the experimental area that interfere in the assessment of possible skin reactions (pigmentation disorders, vascular malformations, scars, increased hairiness, large amounts of freckles and warts, sunburn).
Presence of active dermatoses or skin lesions (local and/or disseminated) in the study region.
Carriers of corneal ulcerations, keratoconus, blepharitis, meibomitis, pterygium, chemosis, hyperemia or other active eye diseases of moderate or severe intensity.
History of ineffectiveness, allergic reactions, irritation or intense discomfort sensation to topical products: cosmetics or medicines.
Expected vaccination during the study or up to 3 weeks before the study;
History of pathologies aggravated or triggered by ultraviolet radiation.
Use of non-steroidal anti-inflammatory drugs, corticosteroids, antihistamines, photosensitizers or immunosuppressants up to 2 weeks before the study.
Facial aesthetic or dermatological treatment up to 4 weeks before the study.
Hormonal treatments not stable in the last 3 months.
Hyperpigmentation associated with the use of drugs such as tetracycline, phenothiazides, or amiodarone.
Hyperpigmentation associated with photosensitivity.
Actinic lichen planus;
People directly involved in carrying out this study and their families.
Be participating in another study.
History of non-adherence or unwillingness to adhere to the study protocol.
Intense sun exposure or tanning session up to 15 days before the initial assessment;
Any condition not mentioned above that, in the opinion of the investigator, could compromise the evaluation of the study.
Facility Information:
Facility Name
Kosmoscience Ciência e Tecnologia Cosmética Ltda
City
Campinas
State/Province
SP
ZIP/Postal Code
13041-315
Country
Brazil
12. IPD Sharing Statement
Learn more about this trial
Evaluation of Cutaneous Acceptability and Perceived Effectiveness of a Nasal Spray (Health Care Products)
We'll reach out to this number within 24 hrs